Clinical Cancer Research
Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
Abstract Purpose: Preclinical studies suggest that poly (ADP-ribose) polymerase inhibition enhances tumor immunogenicity through stimulation of IFN genes pathway activation, providing rationale for combination with immune checkpoint inhibitors. However, clinical evidence supporting this synergy remains limited. We conducted a neoadjuvant pilot study evaluating olaparib with or without pembrolizumab in homologous recombination deficiency (HRD)–positive advanced ovarian cancer. Patients and Methods: Patients with new …